Herantis Pharma Oyj Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-6.62	-4.94	0.28	-9.32	-12.77	Upgrade
Other Amortization	-	-	-	0.16	2.72	Upgrade
Other Operating Activities	-0.1	-0.04	-5.13	0.24	-	Upgrade
Change in Accounts Receivable	0.37	-0.18	-0.02	-0.1	0.04	Upgrade
Change in Other Net Operating Assets	0.26	-1.39	0.23	0.08	0.07	Upgrade
Operating Cash Flow	-6.1	-6.55	-4.64	-8.94	-9.93	Upgrade
Investment in Securities	-0.24	-0.47	-	-	-	Upgrade
Other Investing Activities	-	-	0.61	-0.21	-	Upgrade
Investing Cash Flow	-0.24	-0.47	0.61	-0.21	-	Upgrade
Long-Term Debt Issued	1.27	2.16	-	-	-	Upgrade
Short-Term Debt Repaid	-	-0	-0.01	-0.15	-0.01	Upgrade
Long-Term Debt Repaid	-0.01	-	-	-	-	Upgrade
Total Debt Repaid	-0.01	-0	-0.01	-0.15	-0.01	Upgrade
Net Debt Issued (Repaid)	1.26	2.15	-0.01	-0.15	-0.01	Upgrade
Issuance of Common Stock	5.19	-	4.51	8.71	4.04	Upgrade
Financing Cash Flow	6.46	2.15	4.5	8.56	4.03	Upgrade
Miscellaneous Cash Flow Adjustments	-0	-	-	-	-	Upgrade
Net Cash Flow	0.12	-4.87	0.47	-0.59	-5.9	Upgrade
Free Cash Flow	-6.1	-6.55	-4.64	-8.94	-9.93	Upgrade
Free Cash Flow Margin	-3424.16%	-	-	-	-	Upgrade
Free Cash Flow Per Share	-0.26	-0.33	-0.27	-0.61	-0.97	Upgrade
Cash Interest Paid	-	0.01	0.55	1.09	0.31	Upgrade
Levered Free Cash Flow	-3.53	-4.72	0.3	-4.76	-5.13	Upgrade
Unlevered Free Cash Flow	-3.31	-4.72	0.31	-4.72	-5.09	Upgrade
Change in Working Capital	0.63	-1.57	0.22	-0.02	0.11	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.